The effects of synbiotic supplementation on metabolic factors and systemic inflammation in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study

CURRENT STATUS: POSTED

Aynaz Velayati
Shaheed Beheshti University of Medical Sciences

Iman Kareem
Shaheed Beheshti University of Medical Sciences

Meghdad Sedaghat
Shaheed Beheshti University of Medical Sciences

Golbon Sohrab

Omid Nikpayam
Tabriz University of Medical Sciences

Mehdi Hedayati
Shaheed Beheshti University of Medical Sciences

Khadijeh Abhari
Shaheed Beheshti University of Medical Sciences

Ehsan Hejazi
Shaheed Beheshti University of Medical Sciences

DOI:
10.21203/rs.3.rs-16649/v1

SUBJECT AREAS
Endocrinology & Metabolism  Nutrition & Dietetics

KEYWORDS
Type 2 diabetes, synbiotic, inflammation, glycemia, lipid profiles
Abstract
Background: Type 2 diabetes is a common metabolic disorder in the world, and it has become a challenge for the health system. Some studies have indicated the desirable effects of synbiotics on metabolic factors in patients with diabetes. Aim: This study aimed to determine the effect of synbiotic supplementation on metabolic factors and systemic inflammation in patients with type 2 diabetes mellitus.

Methods: In this randomized, double-blind controlled trial, 50 patients with type 2 diabetes randomly allocated to the synbiotic (containing Bacillus coagulans + Lactobacillus rhamnosus + Lactobacillus acidophilus and fructooligosaccharide) or placebo groups to received one sachet daily for 12 weeks. Glycemic index, Lipid profile, and hs-CRP measured at the beginning of the study and the end of the 12th week.

Results: After 12 weeks, supplementation means a change of Hip circumference (HC) significantly decreased in the synbiotic group compared to the placebo group (-0.85±1.89 vs. 1.23±3.98). Although systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the end of trial declined in the synbiotic group compared to baseline, respectively p=0.03, p=0.01. Analysis of covariance demonstrated that synbiotic supplementation during 12 weeks significantly reduced glycemic factors including fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p<0.05) and inflammatory index, hs-CRP (p<0.05) compared to placebo.

Conclusion: The current study indicated Synbiotic supplementation could improve glycemic index, systemic inflammation and blood pressure in patients with type 2 diabetes. So correcting the intestinal microbial flora can be a new therapeutic approach to treating this disease.

Trial registration: IRCT, IRCT20100524004010N27. Registered 7 January 2019, https://www.irct.ir/trial/36535

Background
Diabetes mellitus (DM) is one of the most common and crucial metabolic diseases in the world. The rapid increase in the prevalence of diabetes is the most severe and challenging health problem of the
21st century worldwide [1]. Type 2 diabetes is a multifactorial disorder and various factors involved in this disorder, such as genetic, epigenetic, environmental and lifestyle factors [2, 3]. Macro- and microvascular complications occur in patients with poorly controlled diabetes that have irreversible on the body. Microvascular complications include nephropathy neuropathy and retinopathy, and macrovascular complications can be attributed to cardiovascular disease, which is one of the most critical risk factors for the death of these patients [4]. It demonstrated that in type 2 diabetes, abrupt metabolic pattern balance, although increase serum concentration of inflammatory cytokines and oxidative stress [5].

Nowadays, many studies are underway to investigate the benefits of functional foods, which one of the important aspects of this research is the anti-diabetes effects of these foods [6]. Probiotics are living microorganisms that, when existed insufficient amounts, have beneficial effects to the host [7]. Probiotics are digestive-resistant micro-organisms that have the ability to adherence to gastrointestinal and already have been proved probiotics is necessary for the balance of population pathogenic bacteria [8]. These compounds are recommended for the prevention and treatment of various conditions and diseases. Their mechanism of action is multifactorial, but most of its function is due to the regulation of immune function [9]. Probiotics can be effective in controlling blood sugar by blocking the production of reactive oxygen species, antioxidant properties and increasing the bioavailability of diabetes drugs [10]. In addition, certain species of probiotics enhance the function of the gut barrier [11] and may reduce the displacement and leakage of microorganisms and their derivatives, including lipopolysaccharides into the portal vein [12]. Recently the effect of probiotics has been investigated in various fields. Human studies have shown that use from probiotic supplements or products containing it improves fasting plasma glucose [13-15] and glycosylated hemoglobin [14, 16], but one study indicated that probiotics did not have any effects on glycemic indexes [17].

The main concern with probiotics application is these microorganisms are vulnerable to gastric acid and bile acids, but Bacillus coagulans is a spore-forming bacterium, can survive through the gastric and duodenal environment [7]. The aim of this study was to assess the effects of bacillus coagulans
and fructooligosaccharide as a synbiotic supplement on metabolic factors and systemic inflammation in patients with type 2 diabetes.

Material Participants and Ethics Statements
This study was a randomized double-blind, placebo-controlled trial which was on patients with type 2 diabetes, the participants were recruited from the diabetes clinic of Imam Hossein hospital in Tehran, Shahid Beheshti University of Medical Sciences. Type 2 diabetes was diagnosed according to fasting blood glucose (FBG) of > 126 mg/dL or 2-h postprandial glucose concentrations of > 200 mg/dL[18].

Patients with type 2 diabetes who were volunteer, BMI in the rage of 18.5–30 kg/m², aged 40-70 years included in the study. Exclusion criteria were pregnancy, insulin administration, consuming synbiotics and/or probiotics supplements within the past 3 months, changing the type and dosage of medications during the study, liver disease, renal failure, hypo- or hyperthyroid and inflammatory disease. This study was approved by the ethics committee of National Nutrition and Food Technology Research Institute (NNFTRI) of Shahid Beheshti University of Medical Sciences and it was registered at Iranian Registry of Clinical Trials, with the registration number of IRCT20100524004010N27, hence performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Study Design
At the beginning of the study, all volunteers completed the written informed consent then block randomization was conducted to allocate the participants in symbiotic or placebo group. The bottle of sachets encoded by A and B by the company, researchers and patients were not aware of the type of supplement. Placebo and symbiotic sachet were the same in color, size, packaging, and shape, and they were produced by the same pharmaceutical company (Magnolia Co, Iran). A technician did a randomized allocation of people to the groups. Symbiotic and placebo groups were received one sachet daily for 12 weeks. Each 2 g sachet contained $10^{11}$ spores of B. coagulans GanedenBC30 (GBI-30, 6086) + $10^{10}$ cfu Lactobacillus rhamnosus GG + $10^9$ cfu Lactobacillus acidophilus and 500 mg fructooligosaccharide (FOS) + 0.7% Natural Orange flavor (Magnolia Co, Iran). Placebo sachets were
filled by 2 g of starch + 0.7% Natural Orange flavor (Magnolia Co, Iran).

Dietary Assessment
Dietary intake was assessed at the baseline and end of the study using a three-day food record (Two workday and one weekend). Researchers were interviewed by patients about the report their intake and then all measures converted to the gram and analyzed for macro- and micronutrients by Nutritionist IV (N4) software.

Anthropometric And Blood Pressure Assessments
The anthropometric measurements including weight, waist circumference (WC) and hip circumference (HP) were measured at baseline and end of the trial also body mass index (BMI) was computed before and after supplementation. Participants' weight was measured without shoes and wearing light clothes to the nearest 0.1 kg, using Seca digital scale digital scales, also Height was measured barefoot to the nearest 1 cm, using a meter attached to the wall. The waist circumference was determined in the middle area of the iliac crest and the last gear and hip circumference in the largest environment with the Seca head circumference meter. All measurements conducted by a person who was a nutritionist. Also, blood pressure variables including systolic blood pressure (SBP) and diastolic blood pressure (DBP) measured twice after a 10-minute respite by a digital blood pressure monitor with 1 mmHg precision. the average of two values included in analysis.

Biochemical Assessments
Glucose was measured using Pars Test kit (Parsazmun, Tehran, Iran) and by enzymatic colorimetric method (GOD-PAP method). In this method, glucose oxidation is measured by enzymatic oxidation by glucose oxidase. The resulting color intensity increases with the concentration of glucose in the serum. The red wavelength was 495 nm. Serum insulin concentration was measured using ELISA method (Dmeditec, Germany) with a sensitivity of 1.76 µLu / ml. Triglyceride (TG) concentration was measured using Pars Test kit (Parsazmun, Tehran, Iran) enzymatically. Total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) concentration was measured by the enzymatic method using Pars Test Kit (Parsazmun, Tehran, Iran). Low-density lipoprotein cholesterol (LDL-C) concentration was also calculated using Friedewald's formula: \( \text{LDL-C (MF)} = \text{Total cholesterol -TG/6 - (HDL-C)} \). Insulin resistance was calculated using the homeostatic model assessment of insulin
resistance (HOMA-IR) formula (HOMA-IR = [FBG (mg / dL) / Fasting Insulin (µU / ml)] / 405). Also, insulin sensitivity was calculated using the quantitative insulin sensitivity check index (QUICKI) formula (QUICKI = 1 / [log fasting insulin (µU / ml) + log fasting glucose (mg / dl)]) and the function of β-pancreatic cells was calculated using the HOMA-β model (HOMA-β = 360 × Insulin (µU / ml) / Fasting glucose (mg / dl) – 63). Finally, the concentration of the hs-CRP was measured by using ELISA kit (IBL, Germany, REF: EU59151).

Statistical Analysis And Sample Size
In this study that is anticipated symbiotic supplementation causes 20 mg/dl reduction in FBG according previous study [15], also with consideration 80% power (1-β) and α = 0.05, the minimum sample was calculated in each group 22 subjects and with considering 10% dropout the sample size increased to 25 subjects in each group. Mean ± standard deviation (SD) and frequency (percent) used for reporting quantitative and qualitative variables, respectively. The Normal distribution of variables was examined by the Kolmogorov-Smirnov test. For comparing qualitative and quantitative confounder variables between two groups Chi-square and Independent sample t-test were used, respectively. To determine differences for quantitative variables within groups paired-samples t-test and between groups, independent samples t-test were applied. Analysis of covariance was performed to comparing the quantitative variables between two groups and adjustment the effects of baseline and confounder variables. P-value < 0.05 consider as significant statistically. All analysis was done with the Statistical Package for Social Science version 21 (SPSS Inc., Chicago, Illinois, USA).

Results
In this study, 50 patients with type 2 diabetes participated, 25 of them in the synbiotic group and 25 in the placebo group. During the study, five patients were excluded from the synbiotic group due to their lack of willingness to cooperate, insulin injection and substitution in the drug. In the placebo group, two persons were excluded from the study due to a lack of willingness to cooperate and changes in the type of drug used (Fig. 1). Totally 20 patients (12 women and 8 men) in the synbiotic group and 23 patients (14 women and 9 men) in the placebo group at the completed study. This study was carried out from October 2018 to February 2018.
Table 1 shows the general characteristics of patients in both groups. The mean age of patients in the symbiotic and placebo group was 59.10 ± 9.71 and 60.39 ± 6.74, respectively. There were not any significant differences in general information between two groups (Table 1).

| variables                  | Symbiotic groups | Placebo group | P value |
|----------------------------|------------------|---------------|---------|
| Age (year)                 | 9.71 ± 59.10     | 6.74 ± 60.39  | 0.612   |
| Gender (%)                 |                  |               |         |
| Men                        | 12 (60%)         | 14 (61%)      |         |
| Women                      | 8 (40%)          | 9 (39%)       |         |
| Smoking (%)                |                  |               |         |
| Yes                        | 0 (0%)           | 3 (13%)       |         |
| No                         | 20 (100%)        | 20 (87%)      |         |
| Hypoglycemic agents (%)    |                  |               |         |
| Yes                        | 16 (83%)         | 21 (90%)      | 0.780   |
| No                         | 4 (17%)          | 2 (10%)       |         |
| Lipid lowering drugs (%)   |                  |               |         |
| Yes                        | 12 (52%)         | 10 (50%)      | 0.460   |
| No                         | 11 (48%)         | 10 (50%)      |         |
| Blood pressure lowering drugs (%) |      |               |         |
| Yes                        | 15 (65%)         | 13 (65%)      | 0.650   |
| No                         | 8 (35%)          | 7 (35%)       |         |

All variables analyzed by except age which were analyzed by t-independent test, p:0.05

Dietary intakes of subjective in both groups at baseline and end of the trial presented in Table 2.

Statistical analysis between two groups at the beginning and end of the trial did not show any significant difference also the amounts of changes in dietary intake within groups during the intervention were not significantly.

| Nutrient                  | Time of assessment | Symbiotic group | Placebo group | P** |
|---------------------------|--------------------|-----------------|---------------|-----|
| Energy (kcal/d)           | Baseline           | 494.9 ± 1930.5  | 671.8 ± 1852.8 | 0.664 |
|                           | End of study       | 469.5 ± 1977.2  | 566.7 ± 1810.06 | 0.303 |
|                           | P*                 | 0.497           | 0.565         |     |
| Carbohydrate (g/d)        | Baseline           | 72.67 ± 257.36  | 109.76 ± 247.35 | 0.731 |
|                           | End of study       | 72.01 ± 256.62  | 86.60 ± 233.84 | 0.358 |
|                           | P*                 | 0.191           | 0.161         |     |
| Protein (g/d)             | Baseline           | 24.99 ± 76.64   | 18.23 ± 65.02  | 0.091 |
|                           | End of study       | 26.12 ± 82.79   | 22.05 ± 73.54  | 0.215 |
|                           | P*                 | 0.187           | 0.064         |     |
| Fat (g/d)                 | Baseline           | 23.29 ± 72.5    | 27.89 ± 72.49  | 0.999 |
|                           | End of study       | 20.72 ± 74.05   | 21.28 ± 69.04  | 0.440 |
|                           | P*                 | 0.719           | 0.290         |     |
| Vitamin E (mg/d)          | Baseline           | 8.87 ± 20.74    | 7.90 ± 21.19   | 0.863 |
|                           | End of study       | 7.96 ± 22.33    | 7.17 ± 20.84   | 0.523 |
|                           | P*                 | 0.332           | 0.732         |     |
| Vitamin C (mg/d)          | Baseline           | 94.99 ± 131.88  | 72.03 ± 117.07 | 0.565 |
|                           | End of study       | 106.92 ± 145.45 | 72.11 ± 118.57 | 0.390 |
|                           | P*                 | 0.604           | 0.898         |     |

P*: p-value for comparison within groups
P**: p-value for comparison between groups

The mean ± standard deviation of anthropometric measurements and blood pressure of patients in the two groups at the beginning and end of the study is shown in Table 3. Differences in weight, BMI,
waist circumference and hip circumference between two groups were not significant differences between the two groups at the beginning and end of the study (P > 0.05). Within-group analysis for all anthropometric measurements did not show any significant changes in synbiotic and placebo groups (P > 0.05). Although the mean changes of hip circumference were significantly different in the synbiotic group compared to the placebo group (P = 0.012). Between-group analysis showed that end of trial DBP significantly decreased in the synbiotic group compared to the placebo group (p = 0.01), although within-group analysis demonstrated that SBP declined significantly in the synbiotic group (p = 0.03), other analysis did not show any significant change in blood pressure values (Table 3).

### Table 3

| Variables | Time          | Symbiotic group | Placebo group | P* |
|-----------|---------------|-----------------|---------------|----|
| Weight (kg) | Baseline     | 71.13 ± 15.96  | 72.63 ± 10.35 | 0.713 |
|           | End of trial | 70.93 ± 16.04  | 72.81 ± 10.80 | 0.650 |
|           | Mean change  | -0.2 ± 2.50     | 0.18 ± 1.43   | 0.472 |
| BMI (Kg/m²) | Baseline     | 27.32 ± 4.34   | 28.27 ± 2.54  | 0.398 |
|           | End of trial | 27.20 ± 4.10   | 28.32 ± 2.54  | 0.458 |
|           | Mean change  | -0.11 ± 0.89    | 0.679         | 0.585 |
| WC(Cm)    | Baseline     | 87.70 ± 8.82   | 90.13 ± 3.96  | 0.266 |
|           | End of trial | 87.00 ± 9.39   | 90.26 ± 3.98  | 0.161 |
|           | Mean change  | -0.7 ± 2.34     | 0.13 ± 2.20   | 0.788 |
| HC(Cm)    | Baseline     | 97.55 ± 8.41   | 95.78 ± 3.87  | 0.396 |
|           | End of trial | 96.70 ± 8.31   | 97.02 ± 4.54  | 0.012 |
|           | Mean change  | -0.85 ± 1.89    | 1.23 ± 3.98   | 0.828 |
| SBP (mm/Hg) | Baseline    | 11.70 ± 0.92   | 12.23 ± 1.49  | 0.171 |
|           | End of trial | 11.10 ± 0.91   | 11.97 ± 1.65  | 0.403 |
|           | Mean change  | -0.6 ± 1.14     | -0.26 ± 1.41  | 0.254 |
| DBP (mm/Hg) | Baseline    | 7.15 ± 0.87    | 7.52 ± 1.12   | 0.238 |
|           | End of trial | 6.55 ± 0.75    | 7.18 ± 0.76   | 0.010 |
|           | Mean change  | -0.60 ± 0.94    | -0.33 ± 1.02  | 0.393 |

P*: p-value for comparison between group by independent t test
P**: p-value for comparison within group by paired t test
P***: p-value for comparison by Ancova (adjusted for baseline values)
BMI: Body mass index, WC: Waist circumference, HC: Hip circumference, SBP: Systolic blood pressure, DBP: Diastolic blood pressure.

Mean baseline, end of the trial and mean changes values of lipid profile including TC, TG, LDL-C, and HDL-C in the placebo and synbiotic group presented in Table 4, comparison between two groups did not show any significant difference except TG at baseline (p = 0.004). Although analysis of covariance demonstrated that supplementation with synbiotic did not any effect on lipid profile (p > 0.05).
### Table 4
Biochemical profile in both group

| Variables                | Groups          | assessment time | Mean change | p*** | p*** |
|--------------------------|-----------------|-----------------|-------------|------|------|
|                          |                 | baseline        | End of study| p**  | p*** |
| Triglyceride (mg/dl)     | symbiotic       | 47.17 ± 173.00  | 46.23 ± 168.15 | 37.70 ± 4.85- | 0.545 | 0.589 |
|                          | placebo         | 52.32 ± 126.39  | 44.21 ± 121.13 | 36.67 ± 5.26- | 0.499 | 0.971 |
|                          | p*              | 0.004           | 0.120        | 0.545 | 0.971 |
| Total cholesterol (mg/dl)| symbiotic       | 46.68 ± 180.95  | 34.52 ± 169.50 | 42.31 ± 11.45- | 0.241 | 0.064 |
|                          | placebo         | 47.29 ± 179.82  | 47.87 ± 174.27 | 31.06 ± 5.04- | 0.444 | 0.878 |
|                          | p*              | 0.938           | 0.684        | 0.571 | 0.878 |
| HDL-C (mg/dl)            | symbiotic       | 9.55 ± 34.76    | 5.29 ± 32.57  | 8.33 ± 2.19- | 0.254 | 0.068 |
|                          | placebo         | 2.96 ± 31.05    | 4.06 ± 32.10  | 3.81 ± 1.04  | 0.202 | 0.068 |
|                          | p*              | 0.109           | 0.744        | 0.122 | 0.068 |
| LDL-C (mg/dl)            | symbiotic       | 180.87 ± 52.69  | 170.56 ± 40.33 | -16.82 ± 56.44 | 0.241 | 0.064 |
|                          | placebo         | 52.55 ± 174.05  | 54.05 ± 166.90 | 34.75 ± 7.65- | 0.276 | 0.571 |
|                          | p*              | 0.678           | 0.805        | 0.519 | 0.571 |
| FBG (mg/dl)              | symbiotic       | 39.17 ± 163.00  | 32.48 ± 146.85 | 39.12 ± 16.75- | 0.254 | 0.068 |
|                          | placebo         | 39.26 ± 144.43  | 40.40 ± 147.65 | 14.54 ± 3.21  | 0.202 | 0.068 |
|                          | p*              | 0.136           | 0.744        | 0.122 | 0.068 |
| Insulin (Mu/ml)          | symbiotic       | 7.25 ± 16.87    | 4.56 ± 9.80   | 16.32 ± 10.50- | <0.0001 | 0.024 |
|                          | placebo         | 5.78 ± 16.99    | 4.46 ± 18.27  | 6.30 ± 1.33  | 0.338 | 0.338 |
|                          | p*              | 0.925           | <0.0001      | 0.03  | 0.338 |
| HOMA-IR                  | symbiotic       | 2.82 ± 6.50     | 2.08 ± 3.68   | 2.62 ± 2.82- | <0.0001 | <0.0001 |
|                          | placebo         | 2.43 ± 5.98     | 2.86 ± 6.73   | 2.7 ± 0.75   | 0.128 | 0.128 |
|                          | p*              | 0.519           | <0.0001      | <0.0001 | 0.128 |
| HOMA-β                   | symbiotic       | 74.30 ± 46.37   | 45.32 ± 22.93 | -28.98 ± 44.84 | 0.009 | <0.0001 |
|                          | placebo         | 66.52 ± 99.31   | 46.37 ± 94.63 | 48.19 ± 4.68- | 0.645 | 0.645 |
|                          | p*              | 0.166           | >0.0001      | 0.096  | 0.645 |
| QUICKI                   | symbiotic       | 0.017 ± 0.296   | 0.025 ± 0.323 | 0.025 ± 0.026 | <0.0001 | 0.948 |
|                          | placebo         | 0.015 ± 0.299   | 0.014 ± 0.294 | 0.013±0.004 | 0.101 | 0.101 |
|                          | p*              | 0.650           | >0.0001      | >0.0001 | 0.101 |
| hs-CRP (ng/ml)           | symbiotic       | 6.53 ± 3.01     | 4.12 ± 3.05   | -2.41 ± 2.48 | <0.0001 | 0.001 |
|                          | placebo         | 5.53 ± 2.04     | 6.47 ± 6.47   | 0.89 ± 3.21  | 0.146 | 0.146 |
|                          | p*              | 0.219           | 0.042        | 0.001  | 0.146 |

P*: p-value for comparison between group by independent t test
P**: p-value for comparison within group by paired t test
P***: p-value for comparison by Ancova (adjusted for baseline values)

After supplementation with synbiotic, within-group analysis showed that insulin, HOMA-IR, HOMA-B, and QUICKI significantly decreased (respectively, p = < 0.001, p = < 0.001, p = < 0.001, p = < 0.001), although statistical analysis showed that mean changes of FBG (p = 0.041), insulin (p = 0.003), HOMA-IR (p = < 0.001) and QUICKI (p = > 0.001) significantly decreased in synbiotic group compared to placebo group. Insulin (p = < 0.0001), HOMA-IR (p = < 0.0001), HOMA-B (p = 0.009) and QUICKI (p = < 0.0001) decreased at the end of the trial compared to baseline in the synbiotic group. Analysis of covariance has been shown that symbiotic supplementation in comparison placebo significantly decreased FBG, insulin, HOMA-IR, and HOMA-B, respectively p = 0.009, p = 0.024, p = < 0.0001, p = < 0.0001 (Table 4).
The mean and standard deviation of hs-CRP in baseline and end of the trial is expressed in Table 4, the analysis indicated that hs-CRP decreased in synbiotic compared to placebo (p = 0.042), although at end of trial hs-CRP declined in the synbiotic group compared a baseline (p = < 0.0001). Analysis of covariance indicated that synbiotic as compared to placebo attenuated hs-CRP (p = 0.001).

**Discussion**

In this study, receiving synbiotic supplementation (fructooligosaccharide and bacillus coagulans) compared with placebo have desirable effects on insulin resistance, glycemic indexes, hs-CRP and diastolic blood pressure in patients with type 2 diabetes but did not have a significant effect on lipid profile.

Up to our knowledge this is first study that evaluated the effects of bacillus coagulans on type 2 diabetes patients. The findings of this study are consistent with the result of the Malaguarnera et al. [19] they showed that synbiotic supplementation could improve the HOMA-IR index But did not any effect on serum insulin levels in the subjects after 6 months of intervention. The results of this study were consistent with the findings of Thorburn [20], and Englyst et al. [21], In these studies supplementation with oligophytic enzymes reduced the levels of insulin levels. In fact, these studies have shown that foods containing indigestible carbohydrates have a hypoglycemic effect.

The findings of the present clinical trial showed that the concentration of serum triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol in the synbiotic group did not change significantly compared to the baseline and the placebo group. Our results were consistent with the findings of Malaguarnera et al. [19]. In this mentioned study, there was no significant difference in TG and TC concentrations between the two groups at the end of six months of supplementation with bifidobacterialangum and fructo-oligosaccharide with lifestyle modification (exercise and diet). Only serum LDL concentration in the treatment group decreased significantly after 6 months of intervention compared to the placebo group. In another study conducted by Ebrahimi et al. [22] in 2017 on obese patients with type 2 diabetes, serum concentrations of triglyceride, total cholesterol, and LDL-cholesterol in the synbiotic supplemented group did not change significantly compared to the placebo group after 12 weeks of supplementation. However, the serum concentration of HDL-
cholesterol was considerably higher in the synbiotic group than in the placebo group after treatment [22]. Also, Assam et al. did not observe any significant change in lipid profile concentration in the synbiotic group after six weeks in patients with diabetes mellitus [23], The results of this study are in line with the present study.

Human study about the effect of synbiotic supplementation on lipid profile is rare and animal studies have been reported controversy results. In a study by Wang et al. [24], 5-week administration of Lactobacillus Plantarum M2 to cholesterol-rich rats showed a significant decrease in serum TC, LDL, and TG levels, but did not affect HDL concentration. The results of earlier studies were also the same as our study results and consistent with Wang's [25–27]. The contradictory findings in lipid profile concentrations can be attributed to differences in strains used, culture media used for the strains, dosage used in the studies, study designs and treatment periods in the studies. The mechanism of the effect of probiotics is still unclear. Some studies indicated that health promotion effects of synbiotics attributed to inhibition of pathogenic bacteria proliferation, the rectification of intestinal flora, reduction of disease risk. The beneficial effects of prebiotics on serum lipid profiles are via short-chain fatty acids (SCFA). Butyrate inhibits the synthesis of cholesterol in the liver. Acetate, as a cholesterol precursor, stimulates its synthesis in the liver, and propionate probably reduces the rate of cholesterol synthesis in the liver by reducing the use of acetate to synthesize cholesterol. The primary mechanism in reducing serum TG is to decrease lipogenic activity in the liver [28–31].

This study showed that taking synbiotic supplements compared to placebo significantly decrease in the serum concentration of hs-CRP. The findings of the present study were in line with the findings of previous studies. A study by Kekkonen et al. [32] demonstrated that three weeks consume milk containing Lactobacillus rhamnosus, sherman and a species of freadenreichii had desirable effects on hs-CRP. However, in this study expressed that other probiotics such as bifidobacteria and lactobacillus lactis, could not change hs-CRP. Therefore, the type of bacterial strains used and even the duration of the intervention may cause differences in these results. Some other studies also showed that synbiotic supplementation could decrease hs-CRP concentration [19, 33, 34]. The proposed mechanism for the effect of probiotics and prebiotics on serum levels of hs-CRP is due to the
extrahepatic effects of these supplements by reducing adipose tissue mass and subsequently
decreasing IL-6 by adipose tissue, hepatocyte stimulation is lessened, resulting in lower amounts of
hs-CRP being synthesized. Also, modification of the gut microbial flora by using probiotics and
prebiotics is effective in reducing endotoxemia and proinflammatory cytokines by maintaining
intestinal mucosal integrity and reducing intestinal permeability.

This study showed that taking synbiotic supplements compared to placebo reduced diastolic blood
pressure. In addition, systolic and diastolic blood pressure were also significantly decreased within the
synbiotic group. A study by Bahmani et al. [35] showed that 120 grams of synbiotic-enriched bread in
patients with diabetes mellitus for eight weeks did not have any significant effect on systolic and
diastolic blood pressure. The findings of this study are comparable to the present study. In another
study by Mahboobie et al. [36] synbiotic supplements containing 6 bacterial strains with
fructooligosaccharide for 12 weeks in person with diabetes. In this study, systolic and diastolic blood
pressure did not change significantly in the intervention group compared to the placebo group. The
conflicting results of synbiotic supplementation and its effects on systolic and diastolic blood pressure
may be due to different doses of supplementation in studies, duration of intervention, type of disease,
and various bacterial species. However, the precise mechanism of how probiotics and prebiotics work
on blood pressure is unclear. A possible mechanism for improving blood pressure could be the change
in the composition of the microbial flora, the reduction of inflammatory mediators and the increase in
nitric oxide levels.

It is essential to use a probiotic which can survive extreme conditions of the gastric and duodenal
environment. Bacillus coagulans is a spore-forming bacterium, which could tolerate this condition.
The present study had some limitations that should be noted for future research. First, all of the
patients consuming oral hypoglycemic agents; thus, we cannot attribute all hypoglycemic effects to
the symbiotic supplement. Second, due to exclusion criteria considered in this study could limit the
generalizability of the results.

Conclusion
Summary findings of this randomized, double-blind controlled trial showed that taking synbiotic
(Bacillus coagulans, Lactobacillus rhamnosus, Lactobacillus acidophilus and fructooligosaccharide) supplements for 12 weeks could decrease FBG, serum insulin levels, insulin resistance, diastolic blood pressure, hs-CRP, and increased QUICKI compared to the placebo group. Synbiotic supplementation did not cause significant changes in serum levels of lipid profile and systolic blood pressure compared to the control group.

**Abbreviations**

SBP
Systolic blood pressure

DBP
Diastolic blood pressure

HOMA-IR
Homeostatic Model Assessment for Insulin Resistance

HOMA-β
β-cell function

DM
Diabetes mellitus

FBG
Fasting blood glucose

WC
Waist circumference

HP
Hip circumference

QUICKI
Quantitative insulin sensitivity check index

BMI
Body mass index

TG
Triglyceride

TC
Total cholesterol

HDL-C
High-density lipoprotein cholesterol

LDL-C
Low-density lipoprotein cholesterol

Declarations

Authors contribution

A.V, O.NP and G.S designated the study, analyzed and interpreted the data and drafting study; G.S and O.NP supervised the study; M.S diagnose patients; M.H perform laboratory tests; A.V, K.A, E.H writing the manuscript; G.S, I.K O.NP revised the content of manuscript, analysis and final of the version to be published. All authors read and approve the final manuscript.

Acknowledgment

No applicable.

Competing interest

The authors declare that they have no competing interest.

Availability of data and materials

Please contact authors for data request.

Consent for publication

No applicable.

Ethics approval and consent to participate

The study protocol was approved by the ethics committee of the National Nutrition and Food Technology Research Institute of Shahid Beheshti University of Medical Sciences. Written informed consents were obtained from all participants.

Funding

his study was supported by the grant from National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences.

References

1. van den Oever, I.A., et al., Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators of inflammation, 2010. 2010.

2. Cani, P.D., Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clinical Microbiology and
Infection, 2012. 18: p. 50-53.

3. Mengual, L., et al., Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia. Cardiovasc Diabetol, 2010. 9: p. 14.

4. Care, D., Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes care, 2000. 23(2): p. B35-B39.

5. Ferreira, L., et al., Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators of inflammation, 2010. 2010.

6. Mahan Lk, S.S., Reymond J, Krause's food and nutrition care process. medical nutrition therapy for diabetes mellitus and hypoglycemia of nondiabetic origin, 2012. chapter 31.

7. Abhari, K., et al., Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? Eur J Nutr, 2019.

8. Elmer, G.W. and L.V. McFarland, Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterology Clinics, 2001. 30(3): p. 837-854.

9. Iacono, A., et al., Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. The Journal of nutritional biochemistry, 2011. 22(8): p. 699-711.

10. Harisa, G., et al., Oral administration of Lactobacillus acidophilus restores nitric oxide level in diabetic rats. Aust J Basic Appl Sci, 2009. 3(3): p. 2963-2969.

11. Madsen, K., et al., Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology, 2001. 121(3): p. 580-591.

12. Cani, P.D., et al., Selective increases of bifidobacteria in gut microflora improve high-
fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia, 2007. 50(11): p. 2374-2383.

13. Asemi, Z., et al., Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Annals of nutrition and metabolism, 2013. 63(1-2): p. 1-9.

14. Ejtahed, H.S., et al., Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition, 2012. 28(5): p. 539-543.

15. Moroti, C., et al., Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids in health and disease, 2012. 11(1): p. 29.

16. Mohamadshahi, M., et al., Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. BioImpacts: BI, 2014. 4(2): p. 83.

17. Mazloom, Z., A. Yousefinejad, and M.H. Dabbaghmanesh, Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iranian journal of medical sciences, 2013. 38(1): p. 38.

18. American Diabetes, A., 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care, 2019. 42(Suppl 1): p. S13-S28.

19. Malaguarnera, M., et al., Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digestive diseases and sciences, 2012. 57(2): p. 545-553.

20. Thorburn, A., J. Muir, and J. Proietto, Carbohydrate fermentation decreases hepatic glucose output in healthy subjects. Metabolism, 1993. 42(6): p. 780-785.

21. Englyst, K.N., et al., Rapidly available glucose in foods: an in vitro measurement that reflects the glycemic response. The American journal of clinical nutrition, 1999.
22. Tajabadi-Ebrahimi, M., et al., *A Randomized Controlled Clinical Trial Investigating the Effect of Synbiotic Administration on Markers of Insulin Metabolism and Lipid Profiles in Overweight Type 2 Diabetic Patients with Coronary Heart Disease*. Exp Clin Endocrinol Diabetes, 2017. **125**(1): p. 21-27.

23. Asemi, Z., et al., *Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial*. Clinical nutrition, 2014. **33**(2): p. 198-203.

24. Wang, Y., et al., *Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet*. Applied Microbiology and Biotechnology, 2009. **84**(2): p. 341-347.

25. Danielson, A., et al., *Anticholesteremic property of Lactobacillus acidophilus yogurt fed to mature boars*. Journal of Animal Science, 1989. **67**(4): p. 966-974.

26. Hosono, A., *Effect of administration of Lactobacillus gasseri on serum lipids and fecal steroids in hypercholesterolemic rats*. Journal of dairy science, 2000. **83**(8): p. 1705-1711.

27. Paik, H.-D., J.-S. Park, and E. Park, *Effects of Bacillus polyfermenticus SCD on lipid and antioxidant metabolisms in rats fed a high-fat and high-cholesterol diet*. Biological and Pharmaceutical Bulletin, 2005. **28**(7): p. 1270-1274.

28. Lee, H.-Y., et al., *Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice*. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 2006. **1761**(7): p. 736-744.

29. Russo, F., et al., *Inulin-enriched pasta affects lipid profile and Lp (a) concentrations in Italian young healthy male volunteers*. European journal of nutrition, 2008. **47**(8):
30. Tovar, A.R., et al., *The inclusion of a partial meal replacement with or without inulin to a calorie restricted diet contributes to reach recommended intakes of micronutrients and decrease plasma triglycerides: A randomized clinical trial in obese Mexican women.* Nutrition journal, 2012. 11(1): p. 44.

31. Vajro, P., et al., *Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease.* Journal of pediatric gastroenterology and nutrition, 2011. 52(6): p. 740-743.

32. Kekkonen, R.A., et al., *Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults.* World J Gastroenterol, 2008. 14(13): p. 2029-36.

33. Eslamparast, T., et al., *Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.* The American journal of clinical nutrition, 2014. 99(3): p. 535-542.

34. Farrokhian, A., et al., *The effects of synbiotic supplementation on carotid intima-media thickness, biomarkers of inflammation, and oxidative stress in people with overweight, diabetes, and coronary heart disease: A randomized, double-blind, placebo-controlled trial.* Probiotics and antimicrobial proteins, 2019. 11(1): p. 133-142.

35. Bahmani, F., et al., *The consumption of synbiotic bread containing Lactobacillus sporogenes and inulin affects nitric oxide and malondialdehyde in patients with type 2 diabetes mellitus: randomized, double-blind, placebo-controlled trial.* Journal of the American College of Nutrition, 2016. 35(6): p. 506-513.

36. Mahboobi, S., F. Rahimi, and S. Jafarnejad, *Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: a meta-analysis of randomized controlled trials.* Advanced pharmaceutical bulletin, 2018. 8(4): p. 565.
Figures
50 eligible and volunteer patients were randomized

Allocated to synbiotic group (n=25)

Allocated to synbiotic group (n=25)

Excluded (n=5) due to:
1- Lack of willingness to cooperate (n=2)
2- Insulin injection (n=2)
3- Changing in the type of drug (n=1)

Completed the trial (n=20)

Included in analysis (n=20)

Allocated to placebo group (n=25)

Allocated to placebo group (n=25)

Excluded (n=5) due to:
1- Changing in the type of drug (n=1)
2- Lack of willingness to cooperate (n=1)

Completed the trial (n=23)

Included in analysis (n=23)

Figure 1
Flow diagram of the study participants
Figure 1

Flow diagram of the study participants

50 eligible and volunteer patients were randomized

Allocated to synbiotic group (n=25)

Allocated to synbiotic group (n=25)

Excluded (n=5) due to:
1- Lack of willingness to cooperate (n=2)
2- Insulin injection (n=2)
3- Changing in the type of drug (n=1)

Completed the trial (n=20)

Included in analysis (n=20)

Allocated to placebo group (n=25)

Allocated to placebo group (n=25)

Excluded (n=5) due to:
1- Changing in the type of drug (n=1)
2- Lack of willingness to cooperate (n=1)

Completed the trial (n=23)

Included in analysis (n=23)
